Local industrial production of the Sputnik V vaccine is underway: more than 30 investors, 17 countries, and 500,000 doses per week in the region

the Direct investment fund in Russia (RDIF, the sovereign investment fund of the Russian Federation), in charge of financing the Gamaleya Institute in the production of the vaccine Sputnik V, held the traditional meeting of the International Council of Experts (ECM) with the participation of the Russian President Vladimir Poutine and representatives of the investment community, on the occasion of the St. Petersburg International Economic Forum.

More than 30 investors from 17 countries, with more than 15 billion of dollars in managed funds, participated in the Board meeting. The participants discussed the key issues of the international partnership necessary to ensure a breakthrough of investments in the Russian economy and the implementation of high-tech projects in priority areas (health, infrastructure, industrial production, etc.). The coronavirus pandemic, a key issue on the global agenda, was also at the center of the MEC meeting.

An important event during the meeting was the start of industrial production of the world’s first registered vaccine against the coronavirus “Sputnik V ”at facilities in Argentina and Serbia.

This Friday, June 4, a few hours before starting with new restrictions, Alberto Fernández announced – as he had planned Infobae– by videoconference with Vladimir Poutine, that Argentina will start producing the Sputnik V vaccine.

“On Sunday, God willing, a plane will leave Moscow with the active ingredient to immediately start production in Argentina. Vaccines will come with Argentina and also for Paraguay ”, declared the Head of State.

The presentation also participated Marcelo Figueiras, president of the Richmond laboratory, who will be in charge of the local production of Russian inoculation, which two days ago, during an interview with Infobae, advancement, “There is light at the end of the pandemic tunnel. “

Figueiras, indicated that Current plant has the capacity to formulate and package up to 500,000 doses of the Sputnik V coronavirus vaccine per week, although he clarified that the production will be subject to the amount of active ingredient sent from Russia.

RDIF has established a large network of international associations for the production of the “Sputnik V” vaccine. For the first time, the MEC meeting brought together representatives of 25 pharmaceutical companies from 14 countries in which “Sputnik V” is already produced. where production is being established: Hetero, Virchow Group, Panacea Biotec, Stelis Biopharma, Gland Pharma, Wockhardt (India); Hualan Biological Bacterin, TopRidge Pharma, GeneSail Biotech, Shenzhen Yuanxing Gene-Tech (China); GL Rapha, ISU ABXIS (South Korea); Richmond Laboratories (Argentina); União Química (Brazil); Birmex (Mexico); R-Pharm Germany GmbH (Germany); ADIENNE Pharma & Biotech, Avara Liscate Pharmaceutical Services SPA (Italy); Torlak Institute (Serbia); Arabio (Saudi Arabia); Cinnagen Ilaç (Turkey); Cinnagen Group, Actoverco (Iran); “BelMedPreparaty” (Belarus). “Karaganda Pharmaceutical Complex” (Kazakhstan).

In dialogue with Infobae Filgueira also added: “The arrival of the documentation proving the approval of the doses sent to Russia in April, marks a new step in the management of the pandemic in Argentina. We will begin the production process for the Sputnik V vaccine at our current facilities; while at the same time we will start with the construction of what will be the most modern biotechnology plant in the region. And that he will work on multiple scientific projects such as biosimilars and on various technologies for the production of vaccines, including those against adenoviruses such as Sputnik V or messenger RNAs such as those of Pfizer or Moderna, among others. And later they will not all be linked to COVID-19 ″.

The Russian vaccine has already been registered by regulators in 66 countries, with a total population of over 3.2 billion people. “Sputnik V” has been approved for use in countries in virtually all regions of the world, including Europe, North and South America, Africa and Asia. The agreements between the Fund and the partners will guarantee a total production of “Sputnik V” sufficient to vaccinate more than 800 million people per year.

The Russian Direct Investment Fund (RDIF) was founded in 2011 to invest in the capital of companies located mainly on Russian territory, as well as major foreign strategic and financial investors. The fund acts as a catalyst for direct investments in the Russian economy. To date, RDIF has a successful history of jointly implementing more than 90 projects with foreign partners for a total volume of over 2 trillion rubles.

KEEP READING: